Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force
Publication date: Available online 6 April 2020Source: Journal of Geriatric OncologyAuthor(s): Heidi D. Klepin, Nina Rosa Neuendorff, Richard A. Larson, Marije E. Hamaker, Massimo Breccia, Pau Montesinos, Raul Cordoba
Publication date: Available online 30 May 2020Source: Seminars in Cancer BiologyAuthor(s): Xiaohua Lu, Thomas Efferth
Authors: Dong A, Yang W, Huang H, Zhou X, He Z, Yao R, Guo W Abstract Changes in histone H3 lysine 9 trimethylation (H3K9me3) may be related to the development of drug‑resistant acute myeloid leukaemia (AML); insights into the network of H3K9me3 may improve patient prognosis. Patient data were derived from the Gene Expression Omnibus (GEO) database and data from AML cells treated with chidamide, a novel benzamide chemical class of histone deacetylase inhibitor (HDACi), in vitro were derived from ChIP‑seq. Patients and AML cell data were analysed using GEO2R, GOseq, KOBAS, the STRING database and Cytoscape ...
The MD Anderson Cancer Center expert discussed why there is an unmet need for more treatments in patients with IDH1-mutated acute myeloid leukemia.
In conclusion, we highlight a novel and clinically exploitable pathway in high-risk EZH2 mutated T-ALL.
In conclusion, we described a myeloid NKL-code and several deregulated NKL homeobox genes in AML. We identified for NKL homeobox gene NANOG deregulating factors and downstream activities in AML. These data indicate a common oncogenic role of NKL homeobox genes in myeloid malignancies.
CONCLUSION: RIC with busulfan and fludarabine is an effective and safe conditioning regimen for adult ALL patients unfit for myeloablation. PMID: 32469169 [PubMed - in process]
Publication date: August 2020Source: Molecular Immunology, Volume 124Author(s): Eman A. El-maadawy, Mohamed F. Elshal, Rania M. Bakry, Mohamed M. Moussa, SobhyHasab El-Naby, Roba M. Talaat
Publication date: Available online 29 May 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Stefania Crisci, Elvira Pota, Giancarla Iaccarino, Irene Postiglione, Concetta Meo, Sara Mele, Rosaria De Filippi, Antonio Pinto
Publication date: Available online 28 May 2020Source: Cancer CellAuthor(s): Matthew T. Witkowski, Igor Dolgalev, Nikki A. Evensen, Chao Ma, Tiffany Chambers, Kathryn G. Roberts, Sheetal Sreeram, Yuling Dai, Anastasia N. Tikhonova, Audrey Lasry, Chunxu Qu, Deqing Pei, Cheng Cheng, Gabriel A. Robbins, Joanna Pierro, Shanmugapriya Selvaraj, Valeria Mezzano, Marla Daves, Philip J. Lupo, Michael E. Scheurer
Authors: Sun YQ, Li SQ, Zhao XS, Chang YJ Abstract INTRODUCTION: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a curable strategy for acute lymphoblastic leukemia (ALL), especially for adult cases. However, leukemia relapse after allograft restricts the improvement of transplant outcomes. Measurable residual disease (MRD) has been the strongest predictor for relapse after allo-HSCT, allowing MRD-directed preemptive therapy. AREAS COVERED: This manuscript summarizes the detection of MRD in patients with ALL who undergo allo-HSCT, focusing the effects of positive pre-HSCT MRD and post-HSC...